Please use this identifier to cite or link to this item:
http://hdl.handle.net/1843/77188| Type: | Artigo de Periódico |
| Title: | Ulcerative colitis: treatment with biologicals |
| Other Titles: | Colite ulcerativa: tratamento com biológicos |
| Authors: | Fabio Vieira Teixeira Sender Jankiel Miszputen Eduardo Garcia Vilela Aderson Omar Mourão Cintra Damião Andrea Vieira Idblan Carvalho de Albuquerque José Miguel Luz Parente Júlio Maria Fonseca Chebli Orlando Ambrogini Junior Rogerio Saad Hossne |
| Abstract: | The pharmacological treatment of ulcerative colitis (UC) aims to reduce the inflammatory process and maintain remission of symptoms1,2. Despite the therapeutic progress, treatment options for moderate to severe active UC remain limited, due to the partial control obtained with conventional therapy (sulfasalazine, aminosalicylates, glycyclorticoids and immunosuppressants) in a substantial proportion of patients, and the existence of adverse events. Currently, the drugs of choice for the therapeutic approach of these patients are anti-tumor necrosis factor alpha (anti-TNF-α) agents, infliximab, adalimumab, and golimumab, and more recently, the anti-integrin agent (vedolizumab) selective antagonist of this adhesion molecule in the intestine |
| Abstract: | O tratamento farmacológico da retocolite ulcerativa (RU) visa reduzir o processo inflamatório e manter a remissão dos sintomas1,2. Apesar do progresso terapêutico, as opções de tratamento para RU ativa moderada a grave permanecem limitadas, devido ao controle parcial obtido com terapia convencional (sulfasalazina, aminossalicilatos, glicocorticoides e imunossupressores) em uma proporção substancial de pacientes, e a existência de eventos adversos. Atualmente, os medicamentos de escolha para a abordagem terapêutica desses pacientes são os agentes anti-fator de necrose tumoral alfa (anti-TNF-α), infliximabe, adalimumabe e golimumabe, e mais recentemente, o agente anti-integrina (vedolizumabe) antagonista seletivo desta molécula de adesão no intestino |
| Subject: | Colite Ulcerativa Tratamento Farmacológico |
| language: | eng |
| metadata.dc.publisher.country: | Brasil |
| Publisher: | Universidade Federal de Minas Gerais |
| Publisher Initials: | UFMG |
| metadata.dc.publisher.department: | MED - DEPARTAMENTO DE CLÍNICA MÉDICA |
| Rights: | Acesso Aberto |
| metadata.dc.identifier.doi: | https://doi.org/10.1590/1806-9282.65.4.547 |
| URI: | http://hdl.handle.net/1843/77188 |
| Issue Date: | 2019 |
| metadata.dc.url.externa: | https://www.scielo.br/j/ramb/a/YyrcYf6zSFnwGhN4tDfWvDL/?lang=en |
| metadata.dc.relation.ispartof: | Revista da Associação Médica Brasileira |
| Appears in Collections: | Artigo de Periódico |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Ulcerative colitis.pdfA.pdf | 110.96 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.